Bausch + Lomb announced that Health Canada issued a Notice of Compliance approving Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%) for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Vyzulta is the first prostaglandin analog with one of its metabolites being nitric oxide (NO).
“More than 250,000 Canadians have glaucoma, which is a chronic disease that results in vision loss over time. Ninety percent of all glaucoma cases are primary open-angle glaucoma (POAG),” Richard Lajoie, president, Bausch Health, Canada, said in a company news release. “With today’s approval of Vyzulta, doctors and patients with glaucoma now have a new innovative treatment option that can help provide consistent and sustained IOP reduction. High IOP is the only modifiable risk factor that can help slow down the progression of the disease to help patients maintain healthy vision.”
Vyzulta, the first once daily monotherapy with a dual mechanism of action, which targets two pathways to reduce aqueous humor to lower IOP. Following topical administration, Vyzulta is thought to lower intraocular pressure by increasing outflow of aqueous humor through both uveoscleral and trabecular meshwork routes. The innovative treatment is rapidly metabolized in the eye to latanoprost acid (main active metabolite), an F2α prostaglandin analogue, and likely butanediol mononitrate.
The most common ocular adverse events include conjunctival hyperemia, eye irritation, eye pain and instillation site pain. Increased pigmentation of the iris and periorbital tissue and growth of eyelashes can occur.
“Vyzulta (latanoprostene bunod 0.024) represents an evolution in topical monotherapy in Canada in the treatment of glaucoma,” says Dr. Ike Ahmed, assistant professor, University of Toronto; clinical professor, University of Utah; director, Glaucoma & Advanced Anterior Segment Surgery (GAASS) Fellowship, University of Toronto; and research director, Kensington Eye Institute, University of Toronto. “It is a unique molecule that targets two outflow pathways to improve IOP reduction. I am pleased to see that a recognized eye care company like Bausch + Lomb is investing in innovative research to advance the treatment of glaucoma ultimately to help eye care providers and their patients to preserve sight.”
“The dual mechanism of action of latanoprostene bunod ophthalmic solution 0.024 offers glaucoma patients a new option for the treatment of intraocular pressure associated with glaucoma,” says Mahadeo Sukhai, head of research and chief accessibility officer, Canadian National Institute of the Blind (CNIB).